BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. Assets
VANCOUVER, BC , May 29, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance Corporation ("Horizon") have executed a follow-on Amendment ("Amendment") to the Asset Purchase Agreement dated February 11th, 2024 ("APA") for acquiring the entire portfolio of assets and intellectual property based on the DPX™ immune educating platform technology developed by Canadian biotechnology company, IMV Inc.
Section 12 of the February 11 th, 2024 APA is a performance milestone provision for BioVaxys to demonstrate an aggregate capital raise of USD $10M by December 31 , 2024. On December 9 th, 2024, Horizon and BioVaxys initially amended the APA by agreeing to delete the reference to " December 31, 2024 " found in Section 12 and replacing it with the date of " June 30, 2025 ."
This new Amendment of May 29 th, 2025, supersedes and replaces the Section 12 terms of the APA so that the net performance milestone required to be raised in any form (including, but not limited to equity, grants, licensing fees, or loans) is now significantly lowered to USD $2,028,636 . If BioVaxys is successful in meeting this milestone by September 30, 2025 , Section 12 of the APA shall end and be of no further force or effect.
As consideration for Horizon amending the APA, BioVaxys agrees to issue to Horizon 2,800,000 share purchase warrants and 1,200,000 share purchase warrants to Powerscourt Investments XXV LP ("Powerscourt"), with each warrant entitling Horizon and Powercourt the purchase of one whole at a purchase price of $0.06 Canadian Dollars per share at any time on or before May 31 , 2028. Horizon and Powerscourt are the members/owners of HIMV LLC (70%/30%), the party to the APA. All other terms and conditions of the APA to remain the same.
BioVaxys and Horizon have further agreed that Section 7(c)(i) of the APA "Licensing Earn-Out Payments Term" be amended from the original "Eighth anniversary of the Closing Date" found in the last line of Section 7(c)(i) to August 11, 2033. During the Licensing Non-Sales Earn-Out Term, BioVaxys shares a predetermined percentage of net licensing non-sales revenues with Horizon.
The "Licensing Non-Sales Earn-Out Term" refers to payments received from an existing licensee or preexisting potential licensee, ending upon the expiration of the last valid claim of a former IMV patent that is the subject of the license agreement to which such existing licensee or preexisting potential licensee is party, and any other payment received under a license agreement, ending on August 11, 2033 .
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated and unique mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, and DPX+rPA for peanut allergy prophylaxis, as well as several viral vaccines. BioVaxys has licensed its patented liposome-based delivery platform to Zoetis, Inc. and SpayVac-for-Wildlife, Inc. for selected animal health applications.
BioVaxys common shares are listed on the CSE under the stock symbol 'BIOV', trade on the Frankfurt Bourse (FRA: 5LB), and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed " James Passin "
James Passin , Chief Executive Officer
Phone: +1 740 358 0555
Cautionary Statements Regarding Forward Looking Information
This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.
These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.
The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Investors are encouraged to read BioVaxys continuous disclosure documents and audited annual consolidated financial statements which are available on SEDAR at www.sedar.com.
Logo - https://mma.prnewswire.com/media/1430981/5345338/BIOVAXYS_Logo.jpg
SOURCE BioVaxys Technology Corp.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 hours ago
- Globe and Mail
NEW WAVE ANNOUNCES Closing of Non-Brokered Private Placement of Units
VANCOUVER, BC, May 30, 2025 (GLOBE NEWSWIRE) -- New Wave Holdings Corp. (the 'Company' or 'New Wave') (CSE: NWAI, FWB: 0XM0, OTCPK: TRMNF) announces, further to its news release of May 20 and May 29, 2025, that the Company has closed the previously announced non-brokered private placement under the Listed Issuer Financing Exemption (as defined herein) of 7,000,000 units of the Company (the ' Units ') at $0.055 per Unit for gross proceeds of $385,000 (the ' LIFE Offering '). Each Unit consists of one common share in the capital of the Company (a ' Share ') and one transferrable common share purchase warrant (a ' Warrant '). Each Warrant will entitle the holder to purchase one additional Share on or after August 13, 2025 at a price of $0.07 on or before May 30, 2027. The Company intends to use the proceeds for future portfolio investments, supporting current investments and for general working capital. The LIFE Offering was completed pursuant to the listed issuer financing exemption (the " Listed Issuer Financing Exemption") under Part 5A of National Instrument 45-106 - Prospectus Exemptions (" NI 45-106"). The securities issued under the LIFE Offering are not subject to a hold period in accordance with applicable Canadian securities laws. There is a first amended and restated offering document dated May 28, 2025 related to this LIFE Offering (the ' Amended and Restated Offering Document ') that can be accessed under the Company's profile at and on the Company's website at The securities issued pursuant to the LIFE Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. ABOUT NEW WAVE HOLDINGS CORP. New Wave Holdings Corp. (CSE: NWAI, FWB: 0XM0, OTCPK: TRMNF) is an investment issuer that has been focused on supporting innovative and fast-growing companies within the esports, Artificial Intelligence, Blockchain, and Web3 sectors. Investors interested in connecting with New Wave Holdings can learn more about the Company by contacting Geoff Balderson, Chief Financial Officer. ON BEHALF OF THE BOARD of DIRECTORS Anthony Zelen Director
Globe and Mail
5 hours ago
- Globe and Mail
EAT & BEYOND ANNOUNCES PROPOSED NAME CHANGE AND UPDATED INVESTMENT POLICY
VANCOUVER, BC, May 30, 2025 (GLOBE NEWSWIRE) -- Eat & Beyond Global Holdings Inc. (CSE: EATS) (OTCPK: EATBF) (FSE: 988) (' Eat & Beyond ' or the ' Company '), is pleased to announce that it is proposing a name change and an expansion of its Investment Policy to reflect a change in strategic focus. Proposed Name Change Subject to shareholder approval, the Company intends to change its name from 'Eat & Beyond Global Holdings Inc.' to 'Digital Asset Technologies Inc.'. The proposed name change is intended to represent the Company's forward-looking focus on emerging digital and blockchain technologies, while maintaining its core mission of investing in innovative and impactful businesses. Concurrently with the completion of the proposed name change, the Company's trading symbol on the Canadian Securities Exchange is expected to change to 'DATT'. Further details regarding the name change – including the effective date, new CUSIP and ISIN numbers for the Company's common shares, and the date on which trading will begin under the new ticker symbol – will be provided in a subsequent news release. ' The proposed name change marks a meaningful step in the Company's continued evolution," said Young Bann, CEO of Eat & Beyond. " The proposed transition to Digital Asset Technologies Inc. reflects our expanded focus on digital innovation, including blockchain technologies and responsible AI solutions. We believe this new identity better represents the direction of the Company and our broader investment objectives." The Company believes that the new name aligns with its updated Investment Policy and long-term strategy to build a diversified portfolio of companies operating at the forefront of emerging technologies. While the Company will continue to support its legacy investments in the food tech and sustainability sectors, it is now placing increased emphasis on opportunities in blockchain infrastructure, asset tokenization, and ethically grounded AI applications. Updates to Investment Policy The Company has historically focused on investments in the food technology and sustainability sectors. These investments form a key part of the Company's foundation and will remain in place going forward. To complement its existing portfolio, the Company pleased to announce that it has amended and updated its Investment Policy to include a focus on blockchain and related technologies. This includes investments in: Real-World Asset Tokenization: Projects that use blockchain to digitally represent physical or traditional assets. Decentralized Infrastructure: Technologies supporting open, distributed systems. Advanced Trading Analytics: Tools and platforms that support improved data analysis and decision-making in financial markets. The Company's updated investment strategy focuses on supporting ventures that advance innovation in AI, Blockchain, Web3, Fintech, and the broader Information and Communication Technology (ICT) sectors. It aims to invest in technologies that demonstrate solid technical foundations, adhere to ethical practices, incorporate user-focused design, and offer potential long-term societal benefits. The Company intends to support solutions that contribute to the development of digital infrastructure, financial systems, decentralized platforms, and intelligent technologies. The Company is committed to identifying ventures that combine technological advancement with practical, real-world impact. The Company targets both early-stage and growth-stage investments and seeks to provide the capital and strategic support needed for these companies to succeed in a rapidly changing technology landscape. To view the Company's updated Investment Policy, please visit its website at The proposed name change and amended Investment Policy are subject to approval by the Canadian Securities Exchange and the Company's shareholders. About Eat & Beyond Eat & Beyond (CSE: EATS) is a publicly traded investment issuer that identifies and makes equity investments in global companies that are developing and commercializing innovative food tech, sustainability and technology. Led by a team of industry experts, Eat & Beyond provides retail investors with the unique opportunity to participate in the growth of a broad cross-section of opportunities in the alternative food, sustainability and technology sectors. Through its wholly owned subsidiary, Liquidlink AI Corp., the Company has entered the blockchain technology sector with a focus on real-world asset tokenization, decentralized infrastructure, and advanced trading analytics. Learn more: The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved the contents of this press release. For further information: For further information, please contact Young Bann, CEO, young@ Cautionary Note regarding Forward Looking Statements This press release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as, 'subject to', or variations of such words and phrases or state that certain actions, events or results 'may' or 'will' be taken, occur or be achieved. Forward-looking statements in this news release include, but are not limited to, statements regarding the Company's business strategy, current and future investments, the proposed name change, the updated Investment Policy, and the Company's ability to obtain the necessary shareholder and regulatory approvals in connection with the proposed name change and updated Investment Policy. Forward-looking statements are based on assumptions, but the actual results may be materially different from any future expectations expressed or implied by the forward-looking statements. The forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including, but not limited to, the equity markets generally and a failure to obtain the necessary approvals from the Canadian Securities Exchange. Accordingly, readers should not place undue reliance on forward-looking statements.
Globe and Mail
5 hours ago
- Globe and Mail
Lancaster Resources Announces Closing Conditions Met for Lake Cargelligo Acquisition
VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Lancaster Resources Inc. (CSE:LCR) (OTC Pink:LANRF) (FRA:6UF0) (' Lancaster '), is pleased to announce it has received approval from the Canadian Securities Exchange to complete the acquisition of the Lake Cargelligo Gold Project and has today completed the $400,000 non-brokered private placement financing as announced on April 23, 2025, which was fully subscribed. With all key conditions met, Lancaster expects the acquisition to close imminently. Lake Cargelligo Gold Project Highlights: District-scale opportunity: 28,768 hectares in a single, contiguous claim with over 25 km of prospective strike and three primary target zones. High-grade results: Historical sampling includes results up to 204 g/t Au and 273 g/t Ag from rock chips, and up to 16m @ 5.83 g/t Au and 7.20 g/t Ag from channel sampling. 1 Acquisition Terms Under the terms of the definitive agreement, Lancaster will acquire a 100% interest in the Lake Cargelligo Gold Project. The total consideration for the acquisition is payable as follows: $10,000 in cash at closing; 10,000,000 common shares with voluntary resale restrictions, released over a 24-month period in staged tranches starting four months after closing. No finders' fees are payable in connection with the acquisition. The vendors will retain a 2% net smelter returns (NSR) royalty on all mineral production. Lancaster may repurchase 1% of the NSR for $2,000,000. The remaining 1% is subject to a repurchase right at fair market value based on a discounted cash flow valuation. Lancaster must incur $400,000 in exploration expenditures within 12 months of closing as an initial work commitment. Failure to do so, after a 60-day cure period, allows the vendors to reacquire the Project for $10,000. A second work commitment of $3,000,000 over 36 months is optional, with similar cure rights for the vendors to reacquire the Project for $50,000. Milestone payments of up to $3.68 million are payable as follows: $30,000 on completion of the first geophysics program; $50,000 on commencement of the first drill program; $50,000 upon raising $1,000,000 post-closing; $50,000 upon receipt of conditional ASX listing approval; $500,000 on a NI 43-101 or JORC-compliant 1Moz gold resource; $1,000,000 on a NI 43-101 or JORC-compliant PEA for a 1Moz resource; $2,000,000 on a NI 43-101 or JORC-compliant PFS for a 1Moz resource. Management Commentary 'With gold reaching record highs and demand remaining robust, we believe Lake Cargelligo is a timely and strategic addition to our portfolio,' said Lancaster CEO Andrew Watson. 'Our team is preparing a Phase 1 exploration program for Summer/Fall 2025 aimed at unlocking the Project's excellent geological and geochemical potential.' All exploration results are historical in nature and have not been verified by a Qualified Person under NI 43-101. The Company considers these results relevant for exploration purposes but not necessarily indicative of mineralization on the property. Andrew Watson, President and CEO and a Director of the Company, is a Qualified Person as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Watson has reviewed and approved the scientific and technical information contained in this news release. Mr. Watson is not independent of the Company. About Lancaster Resources Inc. Lancaster Resources Inc. is a Canadian exploration company focused on advancing a diversified portfolio of critical mineral and precious metal assets. The Company holds a 100% interest in the Piney Lake Gold Project in Saskatchewan and maintains additional uranium exploration projects at Catley Lake and Centennial East in the Athabasca basin, Saskatchewan, as well as the Alkali Flat Lithium Project in New Mexico. Lancaster has also signed a definitive agreement to acquire the Lake Cargelligo Gold Project in New South Wales, Australia. Andrew Watson, President & Chief Executive Officer, Lancaster Resources Inc. info@ Tel: 604 923 6100 The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release. Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this press release constitute forward-looking information. These statements relate to future events, or Lancaster's future performance. The use of any of the words 'could', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Lancaster's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, the ability of Lancaster to execute its exploration plans, ability to complete the acquisition of the Lake Cargelligo Gold Project, raise capital, retain key personnel, identify, acquire, explore, and develop high-quality mineral-rich properties constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. Lancaster disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws. 1 Sources include: (1) Carpentaria Exploration Ltd., 2014 Annual Report for EL8095; (2) Aberfoyle Exploration Pty Ltd., First and Final Report for EL1770, June 1982; (3) Lachlan Resources N.L., First Six-Month Progress Report for EL2914; and (4) MinView database from the Geological Survey of NSW ( nview).
